Klotho Neurosciences Announces Warrant Repricing Agreement

Klotho Neurosciences ( (KLTO) ) just unveiled an update.

On June 10, 2025, Klotho Neurosciences announced a warrant repricing agreement with investors, reducing the exercise price of over 4.5 million stock warrants to $1.35 per share. This move aims to incentivize investment and potentially enhance shareholder value. Additionally, on June 5, 2025, the company entered a Stock Purchase Agreement to sell 4 million shares for $500,000, leveraging a pre-existing relationship with the purchaser. Furthermore, Klotho Neurosciences revealed promising findings from pre-clinical studies on the Klotho gene, indicating its potential to increase lifespan and reduce age-related degeneration, particularly in neurodegenerative diseases. The company has secured exclusive rights to the s-KL protein, which could significantly impact its market positioning in the biogenetics sector.

More about Klotho Neurosciences

Klotho Neurosciences, Inc. is a biogenetics company focused on developing innovative cell and gene therapies using a protein derived from the patented ‘anti-aging’ human Klotho gene (s-KL). The company aims to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease through its proprietary cell and gene therapy programs.

Average Trading Volume: 29,051,831

Technical Sentiment Signal: Sell

Current Market Cap: $6.66M

Find detailed analytics on KLTO stock on TipRanks’ Stock Analysis page.